High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease

NCT02027090 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Routine dose icotinib
DRUG: Higher dose icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.